Search Result

Results for "

human whole blood

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) CD38 (1) Cholinesterase (ChE) (1) Complement System (1) COX (6) CXCR (1) Epigenetic Reader Domain (2) FLAP (4) Glucocorticoid Receptor (1) Histamine Receptor (1) IFNAR (1) Interleukin Related (2) Isotope-Labeled Compounds (1) JAK (2) Leukotriene Receptor (4) Lipoxygenase (3) MAP3K (2) P2X Receptor (1) PGE synthase (1) Phosphodiesterase (PDE) (2) PPAR (2) Prostaglandin Receptor (2) ROR (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (10) Cardiovascular Disease (3) Endocrinology (3) Inflammation/Immunology (22) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Apoptosis (2)

CD38 (1)

Cholinesterase (ChE) (1)

Complement System (1)

COX (6)

CXCR (1)

Epigenetic Reader Domain (2)

FLAP (4)

Glucocorticoid Receptor (1)

Histamine Receptor (1)

IFNAR (1)

Interleukin Related (2)

Isotope-Labeled Compounds (1)

JAK (2)

Leukotriene Receptor (4)

Lipoxygenase (3)

MAP3K (2)

P2X Receptor (1)

PGE synthase (1)

Phosphodiesterase (PDE) (2)

PPAR (2)

Prostaglandin Receptor (2)

ROR (1)

Toll-like Receptor (TLR) (1)

By Research Areas:

Cancer (10)

Cardiovascular Disease (3)

Endocrinology (3)

Inflammation/Immunology (22)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137892

GSK620	Epigenetic Reader Domain	Inflammation/Immunology
GSK620 is a potent and orally active pan-BD2 inhibitor with excellent broad selectivity, developability and in vivo oral pharmacokinetics. GSK620 is highly selective for the BET-BD2 family of proteins, with >200-fold selectivity over all other bromodomains. GSK620 shows an anti-inflammatory phenotype in human whole blood .

HY-153440

JAK-IN-25	JAK	Cancer
JAK-IN-25 (compound 19) is a potent JAK inhibitor with IC₅₀s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. JAK-IN-25 inhibits human whole blood IL-12 (HEB IL-12) with an IC₅₀ of 28 nM. JAK-IN-25 has the potential for cancer research .

HY-13344

PF-8380 5 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
PF-8380 is a potent autotaxin inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-13344A

PF-8380 hydrochloride 5 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
PF-8380 hydrochloride is a potent autotaxin inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-107275

Ebeiedinone	Cholinesterase (ChE)	Neurological Disease
Ebeiedinone, a steroidal alkaloid from Fritillaria species, inhibits the bioactivity of human whole blood cholinesterase (ChE) at the concentration of 0.1 mM, with the inhibitory effects of 69.0% .

HY-U00170

Bunaprolast U66858	Leukotriene Receptor Prostaglandin Receptor Lipoxygenase	Inflammation/Immunology Endocrinology
Bunaprolast (U66858) is a potent inhibitor of LTB₄ production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB₂ release.

HY-18725A

P2X7-IN-2 TFA	P2X Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology
P2X7-IN-2 TFA (compound 58) is a P2X7 receptor inhibitor. P2X7-IN-2 TFA inhibits IL-Iβ release with an IC₅₀ value of 0.01 nM. P2X7-IN-2 TFA can be used for the research of autoimmunity, inflammation and cardiovascular disease .

HY-106093

Eltenac	COX	Inflammation/Immunology
Eltenac, a non-steroidal anti-inflammatory drug (NSAID), is a COX inhibitor. Eltenac shows IC50 of 0.03 μM for both COX-1 and COX-2 in isolated human whole blood .

HY-151894

I-BET432	Epigenetic Reader Domain	Cancer
I-BET432 is a BET inhibitor. I-BET432 inhibits BRD4 N-terminal bromodomain (BD1) and the C-terminal bromodomain (BD2) with pIC₅₀ values of 7.5 and 7.2, respectively. I-BET432 can be used as an oral candidate quality molecule for the research of multiple oncology and inflammatory diseases .

HY-15321S2

Etoricoxib-d3 MK-0663-d₃; L-791456-d₃	COX
Etoricoxib-d₃ is the deuterium labeled Etoricoxib[1]. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood[2][3][4].

HY-113854

AZD2906	Glucocorticoid Receptor	Cardiovascular Disease Endocrinology
AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC₅₀s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively .

HY-32015

Cot inhibitor-1 2 Publications Verification	MAP3K	Inflammation/Immunology
Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC₅₀ of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC₅₀ of 5.7 nM .

HY-15321

Etoricoxib MK-0663; L-791456	COX	Inflammation/Immunology Cancer
Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC₅₀s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-15321S

Etoricoxib-d4 1 Publications Verification MK-0663-d₄; L-791456-d₄	COX	Others
Etoricoxib-d₄ is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-153254

BMS905	Toll-like Receptor (TLR)	Inflammation/Immunology
BMS905 is an orally active TLR7 and TLR8 dual inhibitor (IC₅₀s: 0.7 and 3.2 nM respectively). BMS905 inhibits TLR7 or TLR8 induced IL-6 production in human/mouse whole blood. BMS905 can be used for research of lupus .

HY-32018

Cot inhibitor-2 2 Publications Verification	MAP3K	Cancer
Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC₅₀ of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC₅₀ of 0.3 μM .

HY-14166

MK-886 Maximum Cited Publications 7 Publications Verification L 663536	FLAP Leukotriene Receptor PPAR Apoptosis	Cancer
MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis .

HY-14166A

MK-886 sodium salt L 663536 sodium salt	PPAR Apoptosis Leukotriene Receptor FLAP	Cancer
MK-886 (L 663536) sodium salt is a potent, cell-permeable and orally active FLAP (IC₅₀ of 30 nM) and leukotriene biosynthesis (IC₅₀s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 sodium salt is also a non-competitive PPARα antagonist and can induce apoptosis .

HY-101448

TMI-1 WAY-171318
TMI-1 is a potent inhibitor of disintegrin metalloenzyme 17 (ADAM17) and other MMPs. TMI-1 inhibits LPS-induced TNF-α secretion in human primary monocytes, and human whole blood . TMI-1 selectively induces caspase-dependent apoptosis in triple negative (TN) and ERBB2-overexpressing breast tumor cell lines .

HY-100864

mPGES1-IN-3	PGE synthase	Inflammation/Immunology
mPGES1-IN-3 (Compound 17d) is a potent and selective microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor, which exhibits excellent mPGES-1 enzyme (IC₅₀: 8 nM), cell (A549 IC₅₀: 16.24 nM) and human whole blood potency (IC₅₀: 249.9 nM) .

HY-15321R

Etoricoxib (Standard) MK-0663 (Standard); L-791456 (Standard)	COX	Inflammation/Immunology Cancer
Etoricoxib (Standard) is the analytical standard of Etoricoxib. This product is intended for research and analytical applications. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC₅₀s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-10797

CJ-42794 1 Publications Verification CJ-042794	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC₅₀ value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers .

HY-150508

MK-0159	CD38	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
MK-0159 is an orally active, potent and selective CD38 inhibitor, with IC₅₀ values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD ⁺ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart .

HY-15321S1

Etoricoxib-13C,d3 MK-0663-¹³C,d₃; L-791456-¹³C,d₃	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Etoricoxib- ¹³C,d₃ is the ¹³C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.

HY-14165A

(S)-Veliflapon (S)-BAY X 1005; (S)-DG-031	Leukotriene Receptor FLAP	Inflammation/Immunology
(S)-Veliflapon ((S)-BAY X 1005) is an orally active inhibitor of leukotriene biosynthesis and 5-lipoxygenase activating protein (FLAP). (S)-Veliflapon inhibits the formation of leukotriene B4 (LTB4) in rat, mouse and human leukocytes with IC₅₀ values of 0.026 µM, 0.039 µM and 0.22 µM respectively. (S)-Veliflapon showes enantioselectivity in human whole blood .

HY-12995A

(S)-BI 665915	FLAP	Inflammation/Immunology
(S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC₅₀ of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC₅₀ of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB₄ production .

HY-128342

Complement C5-IN-1	Complement System	Inflammation/Immunology
Complement C5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5). Complement C5-IN-1 interacts with C5 to prevent its cleavage by the C5 convertase and blocks zymosan-induced the membrane-attack complex (MAC) deposition in 50% human whole blood with an IC₅₀ of 0.77 µM .

HY-136527

BMS-986251	ROR Interleukin Related	Inflammation/Immunology
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC₅₀ of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC₅₀ of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .

HY-150720

TYK2-IN-12	JAK IFNAR	Inflammation/Immunology
TYK2-IN-12 (compound 30) is an orally active, potent and selective TYK2 (tyrosine kinase 2) inhibitor, with a K_i of 0.51 nM. TYK2-IN-12 inhibits IL-12 induced IFNγ, with IC₅₀ values of 2.7 and 7.0 μM in human and mouse whole blood, respectively. TYK2-IN-12 can be used for psoriasis research .

HY-19443

UCB-35440	Histamine Receptor Lipoxygenase	Inflammation/Immunology
UCB-35440 is an orally active histamine H1 receptor antagonist and 5-lipoxygenase inhibitor. UCB-35440 inhibits LTB4 formation in human whole blood and reduces polymorphonuclear cell infiltration in mouse models. UCB-35440 inhibits histamine-stimulated bronchoconstriction and reduces skin inflammation in guinea pigs. UCB-35440 can be used for research on asthma and skin inflammation .

HY-18862

PF-03715455
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC₅₀ values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC₅₀=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .

HY-125975

1-Naphthyl 3,5-dinitrobenzoate	Lipoxygenase	Inflammation/Immunology
1-Naphthyl 3,5-dinitrobenzoate is a potent 5-lipoxygenase inhibitor with IC₅₀ values of 1.04 µM and 3.6 µM for 5-LOX and mPGES-1, respectively. 1-Naphthyl 3,5-dinitrobenzoate has strong inhibition activity in the human whole blood (HWB) assay with an IC₅₀ value of 8.6 μM. 1-Naphthyl 3,5-dinitrobenzoate can be used in research of inflammation .

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM .

Cat. No.	Product Name	Category	Target	Chemical Structure